Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 8, 2025
Reporting period
Not applicable
Filed with the SEC
Nov 27, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001493152-25-025197
Filed / recorded
Nov 27, 2025, 3:24 AM UTC
Added to OQRO
Oct 7, 2026, 10:28 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Kairos Pharma, LTD.
Issuer CIK
1962011
Ticker
KAPA
Reporting person
John S Yu
Relationship
Director, Officer, 10% owner
Officer title
CEO and Chairman
Security
COMMON STOCK
Table
Non-derivative (Table I)
Transaction date
Oct 8, 2025
Transaction code
A
Shares / units
190,840
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
230,105
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date.
Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: changed a top executive or board member, the same day (Oct 8, 2025).